Manuscripts
Showing 1600 manuscripts.
A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research
Citation
Keith J Horvath, Sarah E Rutstein, Ryan P Coyle, Cheryl Jennings, Rahim Z Miller , Justin Unternaher, Kelly Bojan, Grace M Aldrovandi, K Rivet Amico, Peter L Anderson , Nadia Dowshen, Sybil Hosek, Lisa Hightow-Weidman, Mark A Marzinke. A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research. AIDS and Behavior. 2026 May 26; doi: DOI: 10.1007/s10461-026-05155-w. PMID: 42189458.Year
2026
Journal
AIDS and Behavior
Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019
Citation
Michael McKenna, Zrinka Lulic, Ann M Buchanan, Cynthia Brothers , Lionel K Tan, Marcia Wang, Sean Brummel , Lauren Ziemba, Theodore Ruel, Patricia M Flynn, Helena Rabie, Andrew Wiznia. Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019. Journal of the Pediatric Infectious Diseases Society. 2026 Sep 12; piag088. doi: DOI: 10.1093/jpids/piag088. PMID: 42731017.Year
2026
Journal
Journal of the Pediatric Infectious Diseases Society
Study
P1093, IMPAACT 2019
Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model-Based Analysis of Mother-Infant Pairs for Tuberculosis Prevention.
Citation
Priya Jayachandran, Jyoti S Mathad, Nan Zhang, Paula Britto, Lubbe Wiesner, Grace Montepiedra, Jennifer Norman, Ellen Townley, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato, Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Amita Gupta, Kelly E Dooley, Radojka Savic, IMPAACT 2001 Study Team. Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model-Based Analysis of Mother-Infant Pairs for Tuberculosis Prevention. Clinical Pharmacology & Therapeutics. 2026 Oct 15; 10.1002/cpt.70479. doi: 10.1002/cpt.70479. PMID: 42878247; PMCID: PMC13670884.Year
2026
Journal
Clinical Pharmacology & Therapeutics
Study
IMPAACT 2001
Participant acceptability and clinician satisfaction of cognitive behavioural therapy and medication management algorithm compared with enhanced standard care for treatment of depression among youth with HIV
Citation
Emily A. Barr, Kristin Baltrusaitis, Betsy D. Kennard, Graham J. Emslie, Chelsea Krotje, Kevin Knowles, Sarah Buisson, Lauren Bergam, Jaime Deville, Susan Gillespie, Melissa Shikora, Ellen Townley, David E. Shapiro, Larry K. Brown. Participant acceptability and clinician satisfaction of cognitive behavioural therapy and medication management algorithm compared with enhanced standard care for treatment of depression among youth with HIV. Journal of Child & Adolescent Mental Health. 2025 Oct 01; 36(1):108-123. PMID: 39550758; PMCID: PMC12439113.Year
2025
Journal
Journal of Child & Adolescent Mental Health
Study
IMPAACT 2002
Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy
Citation
Ahizechukwu Eke, Sean Brummel, Muktar H Aliyu, Lynda Stranix-Chibanda, George Uchenna Eleje, Ifeanyi Ezebialu, Violet Korutaro, Deo Wabwire, Allen Matubu, Tapiwa Mbengeranwa, Nahida Chakhtoura, Lameck Chinula, Katie McCarthy, Kevin Knowles, Chelsea Krotje, MacRae F Linton, Kelly Dooley, Paul Sax, Todd Brown, Shahin Lockman, IMPAACT 2010/VESTED Study Team. Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy. Clinical Infectious Diseases. 2025 Mar 17; 80(3):594-601. PMID: 39219495; PMCID: PMC11912963.Year
2025
Journal
Clinical Infectious Diseases
Study
IMPAACT 2010
Bone mineral density changes in breastfeeding women living with HIV on antiretroviral therapy in Eastern and Southern Africa
Citation
Flavia Matovu Kiweewa, Lynda Stranix-Chibanda, Nonhlanhla Yende-Zuma, Sufia Dadabhai, Maxensia Owor, Sherika Hanley, Mandisa Nyati, Lameck Chinula, John M. Pettifor, Sean S. Brummel, Jim Aizire, Taha E. Taha, Todd T. Brown, Mary Glenn Fowler, Maternal Bone Health Study Team. Bone mineral density changes in breastfeeding women living with HIV on antiretroviral therapy in Eastern and Southern Africa. AIDS. 2025 Jun 01; 39(7):848-856. PMID: 39918445; PMCID: PMC12455725.Year
2025
Journal
AIDS
Study
P1084s
Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants
Citation
Kathleen M. Powis, Mauricio Pinilla, Flynn McMorrow, Alice Stek, Kristina M. Brooks, David E. Shapiro, Kevin Knowles, Ahizechukwu C. Eke, Elizabeth Greene, Allison Agwu, Lourdes Topete, Renee Browning, Nahida Chakhtoura, Priyanka Arora, Xiaoying Huang, Brookie M. Best, Mark Mirochnick, Jeremiah D. Momper, IMPAACT 2026 Protocol Team. Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants. Journal of Acquired Immune Deficiency Syndromes. 2025 Mar 01; 98(3):300-307. PMID: 39813286; PMCID: PMC11798693.Year
2025
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
IMPAACT 2026
Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial
Citation
Tapiwa Mbengeranwa, Lauren Ziemba, Sean S. Brummel, Ben Johnston, Haseena Cassim, Gerhard Theron, Zukiswa Ngqawana, Deo Wabwire, Katie McCarthy, John Shepherd, Shahin Lockman, Lameck Chinula, Lynda Stranix-Chibanda, IMPAACT 2010/VESTED study team and investigators. Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial. Journal of AIDS. 2025 Jun 01; 99(2):211-219. PMID: 40001275; PMCID: PMC12455726.Year
2025
Journal
Journal of AIDS
Study
IMPAACT 2010
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Citation
Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M. Best, John H. Moye, Ellen Townley, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M. Van Solingen-Ristea, Edmund V. Capparelli, Mark A. Marzinke, Elizabeth D. Lowenthal, Shawn Ward, Chelsea Krotje, Ryan Milligan, Allison L. Agwu, Jenny Huang, Amy Cheung, Cynthia McCoig, Dwight E. Yin, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Aditya H. Gaur, IMPAACT 2017 Collaborators. Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2025 Mar 07; 12(3):e191-e200. PMID: 40049924.Year
2025
Journal
Lancet HIV
Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s.
Citation
Jennifer A. Hughes, Mauricio Pinilla, Kristina M. Brooks, Ahizechukwu C. Eke, Alice Stek, Brookie M. Best, Mark Mirochnick, Renee Browning, Lubbe Wiesner, Kathleen George, Kevin Knowles, Petra De Koker, Nahida Chakhtoura, Anneke C. Hesseling, Eric Decloedt, David E. Shapiro, Marije van Schalkwyk, IMPAACT P1026s Protocol Team. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clinical Pharmacology. 2025 Apr 01; 64(4):619-630. PMID: 40155501; PMCID: PMC12041113.Year
2025
Journal
Clinical Pharmacology
Study
P1026S